Ann: Trading Halt, page-18

Problem as RHT holders have seen for years is that the $ come slowly over a long period so the headline number looks large but is over a extended period. Good base income and of course depending on which test they are referring to it may lead to furthe rbusiness or simply be used in a trial to prove no side issues at a particular dosage of drug and when trial is finished if the drug is approved then no RHT further testing will be required. Other positive option is that the RHT test will be required if drug is appoved at a regular interval by drug users and that would provide a wider base of income for RHT.

The reason for halt may simply be due to timing being a overseas based company who must also report trial and significance to RHT is not a huge hurdle as RHT market cap is so small

Hope for positive news but simply another company using their technology is positive

Does the recent rise look like a leaky ship?